Stockreport

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader [Read more]